$0.41
-0.01 (-1.50%)
Open$0.42
Previous Close$0.41
Day High$0.42
Day Low$0.40
52W High$3.85
52W Low$0.39
Volume—
Avg Volume645.7K
Market Cap14.07M
P/E Ratio—
EPS$-10.78
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,989.2% upside
Current
$0.41
$0.41
Target
$24.85
$24.85
$15.48
$24.85 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.16M | 3.54M |
| Net Income | -163,651 | -194,157 | -147,578 |
| Profit Margin | -3.9% | -4.7% | -4.2% |
| EBITDA | -229,901 | -240,916 | -206,498 |
| Free Cash Flow | -133,630 | -165,029 | -157,801 |
| Rev Growth | +8.4% | +2.1% | +5.7% |
| Debt/Equity | 0.23 | 0.22 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |